TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02031250
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
Study: NCT02031250
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
Study: NCT00412464
Drug: Fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
Study: NCT03232021
Drug: Pregabalin Oral Capsule [Lyrica] 75mg
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
Study: NCT03232021
Drug: Pregabalin Oral Capsule [Lyrica] 150 mg
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
Study: NCT03483051
Drug: Potassium Nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
Study: NCT03483051
Drug: Potassium Chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
Study: NCT03856164
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
Study: NCT01220622
Drug: Nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of nimodipine 30mg tid for 6 months
Study: NCT00087529
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous repeating dose
Study: NCT00922896
Drug: Gemcitabine, Cisplatin, Erlotinib (Tarceva)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks
Study: NCT00163319
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01853722
Drug: DCN01
Normalized name: Dexchlorpheniramine
DrugBank: Dexchlorpheniramine maleate (DB09555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three serial applications per periocular region.
Study: NCT01853722
Drug: Unisol
Normalized name: Flunisolide
DrugBank: Flunisolide (DB00180)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three serial applications per periocular region.
Study: NCT00518986
Drug: armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/day
Study: NCT02660502
Drug: Biochaperone insulin lispro 0.1 U/kg
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
Study: NCT01972230
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04413799
Drug: paravertebral block with ropivicaine
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to PVB, the anesthesiologist led Acute Pain Service (APS) will place a paravertebral block catheter. Ropivacaine infusion will be started, monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups
Study: NCT02660502
Drug: Biochaperone insulin lispro 0.2 U/kg
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
Study: NCT02660502
Drug: Biochaperone insulin lispro 0.4 U/kg
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
Study: NCT02427919
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparison of the effect of G-CSF use
Study: NCT03066427
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50 mg/d
Study: NCT01430442
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimegepant capsules
Study: NCT01430442
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
Study: NCT02977195
Drug: NP137 DL and RP2D
Normalized name: DL-Pantothenol
DrugBank: Panthenol (DB11204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT00494091
Drug: Temsirolimus (CCI-779)
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg/m2 IV TEMSR weekly (Japan, n=6)
Study: NCT00494091
Drug: Temsirolimus (CCI-779)
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg IV TEMSR weekly (all other pts)
Study: NCT03718143
Drug: Combination AZD1775 with AraC
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZD1775 days 1-5 \& 8-12 AraC days 1-5 \& 8-12
Study: NCT01500161
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
Study: NCT00699517
Drug: OMBRABULIN (AVE8062)
Normalized name: Ombrabulin
DrugBank: Ombrabulin (DB12882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion followed by administration of cisplatin
Study: NCT01500161
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
Study: NCT01500161
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
Study: NCT01500161
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
Study: NCT00494897
Drug: Asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00494897
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00494897
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00919113
Drug: 2% sodium chondroitin sulfate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly 20 mL Intravesical instillation
Study: NCT02575651
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
Study: NCT02722421
Drug: Levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
Study: NCT02722421
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive efavirenz-based ART as part of standard of care
Study: NCT00798603
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00798603
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01500161
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
Study: NCT01500161
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
Study: NCT01500161
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
Study: NCT00006097
Drug: CC-1088
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00494897
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00494897
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00142883
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin compared to placebo
Study: NCT03103568
Drug: Nitisinone in Arm A
Normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
Study: NCT03103568
Drug: Tolbutamide
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 500 mg tablet is given as single oral dose 2 weeks apart.
Study: NCT03103568
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
Study: NCT01983501
Drug: Tucatinib (ONT-380)
Normalized name: tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given twice per day, orally
Study: NCT01983501
Drug: T-DM1
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously once every 21 days
Study: NCT03591380
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
Study: NCT03103568
Drug: Chlorzoxazone
Normalized name: Chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 250 mg tablet is given as single oral dose 2 weeks apart.
Study: NCT01768260
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard drug therapy
Study: NCT00966160
Drug: Lopinavir/Ritonavir plus Lamivudine/Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
Study: NCT00966160
Drug: Efavirenz plus Lamivudine/Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
Study: NCT03103568
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
Study: NCT03103568
Drug: Nitisinone in Arm B
Normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
Study: NCT00592969
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00592969
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02782975
Drug: aducanumab
Normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006361
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03993535
Drug: selective serotonin reuptake inhibitor
Normalized name: Selective serotonin reuptake inhibitors
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: open treatment based on patient preference and treatment availability
Study: NCT01285713
Drug: Normal Saline (NS)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
Study: NCT04531943
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
Study: NCT04531943
Drug: Estrogen plus Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
Study: NCT03223779
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine stops DNA replication which may prevent the cancer cells from growing
Study: NCT01127087
Drug: Oxazyme
Normalized name: XomaZyme-791
DrugBank: XomaZyme-791 (DB17216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily.
Study: NCT01933282
Drug: MESA chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
Study: NCT01933282
Drug: MESA
Normalized name: guaimesal
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
Study: NCT00149201
Drug: 5-FU continuous infusion
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00149201
Drug: MTX + 5-FU sequential therapy
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03474770
Drug: BIS-001ER
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
Study: NCT03889444
Drug: Dexamethasone intravitreal implant
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
Study: NCT01412957
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT00274131
Drug: Pramipexole 0.125 mg tablets
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00274131
Drug: Pramipexole 0.5 mg tablets
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005794
Drug: perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03771677
Drug: Interferon Alfa-2A
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180ug per week
Study: NCT00358124
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00358124
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03351777
Drug: PR022
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT00358124
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03334903
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
Study: NCT00353262
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg/kg iv (cycle 3 only)
Study: NCT00353262
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2 iv (cycles 1, 2 and 3)
Study: NCT03591471
Drug: Glycosides Of Tripterygium Wilfordii Hook(GTW)
Normalized name: Tripterygium wilfordii whole extract
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time
Study: NCT00272038
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg QD
Study: NCT03591471
Drug: Prednisone Acetate Tablets
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
Study: NCT03605680
Drug: Centanafadine SR
Normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, BID, oral tablets
Study: NCT03605680
Drug: Centanafadine SR
Normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, BID, oral tablets
Study: NCT03473093
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One group will receive oral pregabalin with morphine infusion
Study: NCT03473093
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One group will receive morphine infusion 20 microgram/kg/h
Study: NCT00003414
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003414
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01275222
Drug: Imatinib 600mg/day (Glevec is the brand name for imatinib)
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.